Collegium Pharmaceutical
COLL
Constellation Brands
STZ
Ermenegildo Zegna NV
ZGN
DexCom
DXCM
Workday
WDAY
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating cash flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 32.08%8.1M | 144.82%4.38M | -17.34%2.85M | -49.14%12.6M | -87.99%1.23M | -31.64%6.13M | -39.20%1.79M | 33.11%3.45M | -20.47%24.78M | 98.24%10.28M |
Net income from continuing operations | 36.59%3.93M | -10.41%3.01M | -17.25%2.78M | 23.87%12.24M | 117.74%2.64M | 15.12%2.88M | 10.85%3.36M | 7.15%3.36M | -45.16%9.88M | -61.49%1.21M |
Operating gains losses | 12.22%-431K | 21.93%-648K | 27.42%-503K | 58.29%-1.02M | 197.30%990K | 29.45%-491K | 22.65%-830K | 31.99%-693K | 78.87%-2.46M | 118.56%333K |
Depreciation and amortization | -24.84%596K | -25.45%583K | -4.69%732K | 20.70%3.11M | -1.03%771K | 35.09%793K | 26.54%782K | 28.86%768K | -0.69%2.58M | 23.45%779K |
Deferred tax | 153.05%200K | -179.73%-414K | -93.05%37K | 133.95%404K | 129.87%397K | -280.38%-377K | 42.86%-148K | 181.48%532K | -247.28%-1.19M | -289.05%-1.33M |
Other non cashItems | -140.58%-756K | 169.36%1.29M | -318.58%-1.85M | -60.96%1.58M | 181.40%726K | -54.75%1.86M | -990.59%-1.85M | 634.81%845K | -78.23%4.05M | -95.23%258K |
Change in working capital | 207.02%4.07M | 430.85%499K | 168.73%1.1M | -145.81%-4.65M | -151.17%-4.47M | -6.49%1.33M | -65.94%94K | -475.18%-1.6M | 8,215.20%10.14M | 343.08%8.73M |
-Change in receivables | -28.18%-1.02M | 1,243.06%967K | -233.67%-131K | -124.80%-1.28M | -110.90%-651K | 50.16%-795K | 256.52%72K | -87.95%98K | 742.23%5.15M | 2,125.08%5.97M |
-Change in payables and accrued expense | 139.95%5.09M | -2,227.27%-468K | 172.48%1.23M | -167.45%-3.37M | -238.51%-3.82M | -29.61%2.12M | -93.17%22K | -55.55%-1.7M | 779.08%5M | 183.59%2.76M |
Cash from discontinued operating activities | ||||||||||
Operating cash flow | 32.08%8.1M | 144.82%4.38M | -17.34%2.85M | -49.14%12.6M | -87.99%1.23M | -31.64%6.13M | -39.20%1.79M | 33.11%3.45M | -20.47%24.78M | 98.24%10.28M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 115.68%3.92M | 90.79%-2.15M | 82.34%-2.67M | 74.33%-50.61M | 126.77%12.79M | 57.84%-25M | 65.96%-23.28M | 79.87%-15.12M | -249.24%-197.16M | 136.87%5.64M |
Proceeds payment in interest bearing deposits in bank | -78.67%518K | -84.90%37K | --0 | 340.16%4.15M | 500.00%984K | 596.52%2.43M | 112.31%245K | -50.55%493K | 9.91%-1.73M | -192.13%-246K |
Net investment purchase and sale | 41.27%22.75M | 3,686.31%14.67M | 202.10%13.21M | 135.89%43.69M | -24.83%23.62M | 190.50%16.1M | 98.62%-409K | 104.14%4.37M | -27.26%-121.73M | 269.12%31.42M |
Net proceeds payment for loan | 50.34%-21.47M | 29.48%-16.23M | 23.80%-15.06M | -32.34%-97.36M | 54.04%-11.35M | -5.97%-43.23M | 37.25%-23.02M | -169.12%-19.77M | -253.79%-73.57M | -782.74%-24.69M |
Net PPE purchase and sale | 1,192.12%2.22M | -542.71%-617K | -269.23%-816K | -296.42%-988K | -117.67%-468K | 8.56%-203K | -123.26%-96K | -122.48%-221K | 169.57%503K | 64.23%-215K |
Net business purchase and sale | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---572K | ---- |
Net other investing changes | ---- | ---- | ---- | -53.97%-97K | ---1K | ---- | ---- | ---- | 98.95%-63K | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 115.68%3.92M | 90.79%-2.15M | 82.34%-2.67M | 74.33%-50.61M | 126.77%12.79M | 57.84%-25M | 65.96%-23.28M | 79.87%-15.12M | -249.24%-197.16M | 136.87%5.64M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -164.90%-14.7M | -70.78%5.19M | -188.05%-10.81M | 563.59%41.95M | 74.42%-10.74M | -67.25%22.65M | 269.77%17.77M | 218.51%12.28M | -95.13%6.32M | -151.20%-42M |
Change in federal funds and securities sold for repurchase | 157.20%783K | -16.75%-7.15M | 134.13%3.18M | -8,285.93%-16.69M | -85.50%124K | -29.89%-1.37M | -1,634.84%-6.12M | -2,235.59%-9.32M | -119.28%-199K | --855K |
Increase decrease in deposit | -7.55%25.02M | -229.50%-43.04M | -243.00%-22.73M | 786.86%15.59M | -75.18%8.22M | 288.86%27.06M | -61.31%-13.06M | 25.68%-6.63M | -98.67%1.76M | -59.53%33.1M |
Net issuance payments of debt | -1,914.36%-39.28M | 48.80%56.61M | -65.65%10.05M | 365.31%47.46M | 76.03%-17.91M | -102.27%-1.95M | 3,324.41%38.05M | --29.27M | --10.2M | -49,244.74%-74.7M |
Net commonstock issuance | ---66K | ---81K | ---174K | 93.95%-75K | 62.31%-75K | --0 | --0 | --0 | ---1.24M | ---199K |
Cash dividends paid | -5.47%-1.16M | -5.02%-1.15M | -4.74%-1.15M | -4.57%-4.39M | -4.75%-1.1M | -4.58%-1.1M | -4.48%-1.1M | -4.48%-1.1M | -9.95%-4.2M | -9.23%-1.05M |
Proceeds from stock option exercised by employees | --0 | --0 | --0 | --52K | --0 | --0 | --0 | --52K | --0 | --0 |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -164.90%-14.7M | -70.78%5.19M | -188.05%-10.81M | 563.59%41.95M | 74.42%-10.74M | -67.25%22.65M | 269.77%17.77M | 218.51%12.28M | -95.13%6.32M | -151.20%-42M |
Net cash flow | ||||||||||
Beginning cash position | 19.22%23.89M | -30.70%16.47M | 17.04%27.1M | -87.76%23.16M | -51.62%23.82M | -34.11%20.04M | -77.65%23.76M | -87.76%23.16M | 123.08%189.21M | -58.03%49.23M |
Current changes in cash | -170.79%-2.68M | 299.17%7.42M | -1,848.85%-10.63M | 102.38%3.95M | 112.58%3.28M | -79.90%3.78M | 95.09%-3.73M | 100.73%608K | -259.07%-166.06M | -136.27%-26.08M |
End cash position | -10.96%21.21M | 19.22%23.89M | -30.70%16.47M | 17.04%27.1M | 17.04%27.1M | -51.62%23.82M | -34.11%20.04M | -77.65%23.76M | -87.76%23.16M | -87.76%23.16M |
Free cash flow | 31.71%7.81M | 122.24%3.76M | -52.17%1.54M | -51.43%11.61M | -92.46%759K | -32.22%5.93M | -41.61%1.69M | 47.06%3.23M | -19.88%23.9M | 125.10%10.06M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- |